要旨
Matcha is not simply green tea in powdered form. It is the entire leaf — steamed, dried, deveined, and stone-ground from shade-grown Camellia sinensis (Theaceae) — consumed whole rather than steeped and discarded. That distinction turns out to matter more than most secondary literature acknowledges. Because the insoluble, fibre-bound fraction of the leaf never leaves the cup, matcha delivers a different catechin dose, and a different physical form of that dose, than a brewed infusion or a milligram-standardised green tea extract (GTE) capsule ever could. Most of what is written about matcha's pharmacology, however, was generated using one of those other two exposures. This review works through the peer-reviewed literature on matcha's botanical origin, cultivation, composition, and pharmacology with that distinction kept in view throughout, flagging section by section which claims rest on matcha itself and which are extrapolated from infusion or extract data. Shade cultivation for 20-35 days before harvest is the physiological event that makes matcha what it is: reduced light slows the enzymatic conversion of amino acids into catechins, so L-theanine accumulates instead of being consumed, while chlorophyll synthesis ramps up to compensate for the light lost. The result is the vivid colour, umami sweetness, and distinctive caffeine-to-theanine ratio that separate matcha from an ordinary green tea leaf — and, among the claims examined here, the ratio with the strongest direct trial support in matcha itself, rather than in a green tea proxy. Mechanistically, EGCG and the other catechins act on several fronts at once rather than through a single pathway: they scavenge reactive oxygen species directly and switch on the cell's own antioxidant machinery through Nrf2, they…
要旨は短縮されています。出典で要旨の全文を読む。
要旨の文章はPubMed、OpenAlex、Europe PMCから取得したもので、著者と出版社に帰属します。